Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Date Time
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
(From left) First and corresponding author Monika Metzger, M.D., Departments of Oncology and Global Pediatric Medicine; co- senior author Matthew Krasin, M.D., Department of Radiation Oncology; and co-senior author Melissa Hudson, M.D., Cancer Survivorship Division director.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children’s Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Children’s Cancer Program and OSF Children’s Hospital of Illinois.